Oral semaglutide vs orforglipron: weight loss compared

Two pills, one choice

For years, every effective GLP-1 came in a needle. Then Novo Nordisk launched the Wegovy pill in December 2025, and Eli Lilly followed with Foundayo (orforglipron) in April 2026. For the first time, people choosing an oral GLP-1 for weight loss have a real comparison to make.

Both drugs activate the GLP-1 receptor. Both require a prescription. Both produce meaningful weight loss. The trial numbers diverge. The dosing requirements diverge. The story is not as clean as one pill beating the other on every measure.

Oral semaglutide vs orforglipron comes down to what you are optimizing for: maximum weight loss, or a simpler daily routine.

What the trial data shows for oral semaglutide vs orforglipron

The weight loss numbers come from different trials. That is the first thing to say plainly, because cross-trial comparisons are inherently imprecise. Different populations, different durations, different dropout handling.

In the OASIS 4 trial, adults with obesity or overweight took oral semaglutide 25mg once daily for 52 weeks. Mean weight loss in the treatment-adherent population was 16.6%. That is comparable to the injectable Wegovy in earlier STEP trials.

In the ATTAIN-1 trial, adults with obesity took orforglipron at doses from 6mg to 36mg for 72 weeks. At the top dose of 36mg, mean weight loss was 12.4%. Lower doses produced 9.3% (12mg) and 7.8% (6mg). ATTAIN-1 ran 20 weeks longer than OASIS 4, which would typically favor more weight loss over time, not less.

An indirect, population-adjusted comparison presented at the Obesity Medicine Association conference in 2026 put the numbers side by side. It found oral semaglutide 25mg produced significantly greater weight loss than orforglipron 36mg. Patient preference surveys showed 84% of respondents favored the profile similar to the Wegovy pill.

Neither number should be read as a verdict. Novo Nordisk funded the indirect comparison. No head-to-head obesity RCT exists. But every available data point points in the same direction: oral semaglutide leads on raw weight loss at maximum doses.

The head-to-head trial and what it actually measured

One direct comparison exists. ACHIEVE-3, published in The Lancet in February 2026, ran orforglipron against oral semaglutide in adults with type 2 diabetes across 50 sites in 10 countries.

Orforglipron reduced HbA1c by 2.2 percentage points and body weight by 9.2%. Oral semaglutide reduced HbA1c by 1.4 points and weight by 5.3%. The trial declared orforglipron noninferior, and in some measures superior, for glycemic control.

There is a critical footnote. The semaglutide comparator in ACHIEVE-3 was 1mg, the older Rybelsus dose approved for diabetes, not the 25mg Wegovy pill approved for obesity. The 25mg dose did not exist when this trial was designed. Rybelsus at 1mg and Wegovy pill at 25mg are the same molecule with very different efficacy profiles. Applying the ACHIEVE-3 result to the Wegovy pill vs Foundayo question in obesity overstates what the trial actually showed.

For people with type 2 diabetes choosing between oral GLP-1 pills, ACHIEVE-3 is genuinely useful. For people treating obesity without T2D, it is incomplete evidence.

The fasting window problem

The Wegovy pill is a peptide. Peptides are destroyed by stomach acid, and food accelerates that process. To get enough drug absorbed, Novo Nordisk built a modified formulation that protects the molecule, but the drug still requires very specific conditions: take it first thing in the morning on a completely empty stomach, with no more than four ounces of water. Then wait 30 minutes before eating, drinking coffee, or taking other medications.

Miss that window, or take it with breakfast, and bioavailability drops sharply. This is not a minor inconvenience for some people. It restructures the start of every day.

Foundayo (orforglipron) is a small molecule, not a peptide. Small molecules survive digestion without special protection. You take Foundayo whenever, with whatever amount of water, before or after food, at any time of day. There is no protocol to follow beyond remembering to take the pill.

For someone who wakes up and immediately makes coffee, eats breakfast, or takes several other medications, the Wegovy pill's requirements are real friction. For someone with a disciplined morning routine, they are trivial. Compliance depends entirely on which category describes you.

Side effects and who stops first

Both drugs produce the GI side effects typical of GLP-1 class treatments: nausea, vomiting, diarrhea, and constipation, particularly during dose escalation. Neither is dramatically different from injectable semaglutide or tirzepatide in this regard.

At maximum doses, the picture shifts. The indirect comparison from OMA 2026 found that orforglipron 36mg was associated with roughly 14 times higher odds of stopping treatment due to GI adverse events compared to oral semaglutide 25mg. That is a large gap.

The caveat applies again: this is not a randomized comparison. Different trial populations, different dropout rates, and Novo Nordisk has a financial interest in the result. But the direction of the finding is consistent with clinical reports of nausea being more pronounced at maximum-dose orforglipron than at the standard Wegovy pill dose. If you tried orforglipron at 36mg and stopped due to side effects, the Wegovy pill may be worth trying, and vice versa.

Cost and what is actually accessible

Foundayo self-pay starts at $149 per month for the lowest dose through LillyDirect. People with commercial insurance and a Lilly savings card can pay as little as $25 monthly. Medicare Part D coverage is expected to average around $50 beginning July 2026.

Oral semaglutide 25mg launched at around the same price point. Novo Nordisk priced it to compete broadly, knowing the injectable Wegovy costs $900 to $1,300 monthly without insurance. Neither pill has a compounded version: compounded semaglutide exists only in injectable form, and orforglipron never entered the FDA shortage list that enabled injectable compounding.

Cost will likely be similar between the two pills for most patients with commercial insurance. Out-of-pocket without coverage is significant for either drug.

Who should take which one

If maximum weight loss is the priority and you can manage a structured morning routine: the data points to oral semaglutide. The OASIS 4 results are stronger, the tolerability picture at maximum doses looks better, and the drug has already shown it can produce weight loss comparable to the injectable version.

If you have type 2 diabetes and glycemic control matters as much as weight: ACHIEVE-3 gives orforglipron a real case. The HbA1c reduction at 2.2 percentage points is clinically meaningful, and the no-restriction dosing makes daily adherence easier for many patients.

If you travel frequently, have an unpredictable schedule, already take multiple morning medications, or have tried oral semaglutide and found the fasting window difficult to maintain: Foundayo's flexibility is a genuine clinical advantage, not just a marketing point. A pill taken reliably at 12.4% efficacy beats a pill taken inconsistently at 16.6%.

The injectable options still produce more weight loss. If efficacy is the single deciding factor and injections are manageable, semaglutide or tirzepatide by injection remain the current ceiling. See the semaglutide vs tirzepatide comparison if you are working through that decision.

For the oral decision specifically: oral semaglutide leads on weight loss, orforglipron leads on convenience. The right choice depends on which tradeoff fits your life. Both drugs work. Neither is obviously dominant for every patient.

If you are considering switching from an injectable to one of these pills, the ATTAIN-MAINTAIN switching guide covers what the trial data shows about transitions from semaglutide and tirzepatide to orforglipron specifically.